"Parkinson's Disease: ProMIS (@ProMISinc) (#TSX: $PMN | #OTCQB: $ARFXF) Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in Development [https://t.co/TAZKelyjMa]#investing"Read full news